Implementation of a Rapid Genotypic Assay to Promote Targeted Ciprofloxacin Therapy of Neisseria gonorrhoeae in a Large Health System.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 28034887.
- Also identified by DOI 10.1093/cid/ciw864 and PMC identifier 5399946.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Multidrug-resistant Neisseria gonorrhoeae is a top threat to public health. In November 2015, UCLA Health introduced a rapid gyrase A (gyrA) genotypic assay for prediction of Neisseria gonorrhoeae susceptibility to ciprofloxacin. We found a significant reduction in ceftriaxone use with a concomitant increase in targeted therapy.
Medical subject headings
- Anti-Bacterial Agents
- Ciprofloxacin
- Genotyping Techniques
- Gonorrhea
- Microbial Sensitivity Tests
- Neisseria gonorrhoeae